Harry Erba, MD, PhD | Authors

Articles

Using MRD to Guide Therapy in AML

September 16, 2017

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB School of Medicine, discusses using MRD to guide therapy in acute myeloid leukemia (AML).

FLT3 Inhibitors in Development for AML

May 29, 2014

Harry Erba, MD, PhD, professor of medicine, director, Hematologic Malignancy Program, University of Alabama at Birmingham, discusses the excitement around FLT3 inhibitors for the treatment of acute myeloid leukemia (AML).